[Expert consensus on the treatment of glioma with radioactive seeds].

Radioactive seeds brachytherapy for glioma has been available for more than half a century. Numerous studies have consistently supported that this therapy is minimally invasive, safe, and effective. Glioma has the potential to form a new treatment paradigm because of low incidence of hematogenous and lymphatic metastases. However, it is difficult to stress the importance of radioactive seeds therapy because of lacking in high-grade evidence achieved from multicenter, prospective, randomized controlled clinical studies. Slow progression in research is mainly due to the complexity of the cranial anatomy and neurological malignancies. Neurosurgeons, oncologists, interventionalists, or imaging physicians all have difficulties in performing radioactive seeds therapy for glioma surgery because technical plights are not overcome by single division. Therefore, to establish a standard and consensus on the treatment of glioma with radioactive seeds will assist in solving the problems and forming a relatively unified treatment procedure and standard, so that this technology can be applied and benefit glioma patients. The article focuses on the treatment standard and consensus related to the technology of radioactive seeds therapy for glioma, composing the basis of consensus formation, the physics basis of radioactive iodine-125 seeds therapy for glioma, clinical application and treatment process.